Impax Laboratories (IPXL) : During the past 4 weeks, traders have been relatively bearish on Impax Laboratories (IPXL), hence the stock is down -0.84% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -10.68% relative to the S&P 500. The 4-week change in the price of the stock is -1.37% and the stock has fallen -10.53% in the past 1 week.
The stock has recorded a 20-day Moving Average of 5.96% and the 50-Day Moving Average is 9.14%.The 200 Day SMA reached 26.41%
Impax Laboratories (NASDAQ:IPXL): After opening at $23.59, the stock dipped to an intraday low of $23.3 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $24.22 and the buying power remained strong till the end. The stock closed at $23.7 for the day, a gain of 0.47% for the day session. The total traded volume was 949,071. The stocks close on the previous trading day was $23.7.
Impax Laboratories (IPXL) : Average target price received by Impax Laboratories (IPXL) is $28.56 with an expected standard deviation of $3.4. The most aggressive target on the stock is $33, whereas the most downbeat target is $24. 9 financial analysts are currently covering the stock.
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. The Company operates in two segments: Impax Generics and Impax Specialty Pharma. The Impax Generics is focused on the development, manufacture, sale and distribution of the Companys generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma is engaged in the development of brand pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Impax Specialty Pharma is also engaged in the sale and distribution of Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.